Cardiovascular and pulmonary vascular disease
Tectonic Therapeutic Inc. focuses on clinical research in pulmonary hypertension linked to heart failure with preserved ejection fraction (HFpEF), with attention to haemodynamic impairment in patients affected by combined postcapillary and precapillary pulmonary hypertension and isolated postcapillary pulmonary hypertension.
- Pulmonary hypertension
- PH-HFpEF
- Combined postcapillary and precapillary pulmonary hypertension
- Isolated postcapillary pulmonary hypertension
The sponsor’s research interest centres on therapies intended to address elevated pulmonary vascular resistance and the clinical burden associated with HFpEF-related pulmonary vascular disease.
Haemodynamic and cardiopulmonary function
Its clinical programme includes evaluation of treatment effects on mean pulmonary vascular resistance and safety in patients with cardiopulmonary disease, reflecting a therapeutic focus on vascular and cardiac interaction in pulmonary hypertension.
- Pulmonary vascular resistance
- Mean PVR
- Cardiopulmonary haemodynamics
- Heart failure-related pulmonary hypertension
Research activity is directed toward clinical settings where elevated filling pressures and pulmonary vascular changes coexist, especially in HFpEF populations.
Heart failure and vascular medicine
The sponsor is engaged in studies at the intersection of heart failure and pulmonary vascular disease, with therapeutic interest in patients whose pulmonary hypertension arises secondary to preserved left ventricular function.
- HFpEF
- Secondary pulmonary hypertension
- Postcapillary pulmonary hypertension
- Pulmonary vascular disease
These studies place emphasis on conditions that are clinically challenging because of overlapping cardiac and pulmonary mechanisms.
